Case Report: An enlarging left ventricular mass during anticoagulation in a patient receiving almonertinib after thoracic radiotherapy: diagnostic uncertainty and individualized management
- 1Department of Oncology and Radiotherapy, Chengdu Qingbaijiang District People’s Hospital , , ,
- 2School of Clinical Medicine, Chengdu Medical College , ,
- 3Department of Oncology, General Hospital of Western Theater Command, People’s Liberation Army , , ,
Abstract
Distinguishing a left ventricular thrombus from a cardiac tumor is challenging when a large mass arises at an atypical non-apical site, particularly in a patient with cancer. We describe a 37-year-old man with epidermal growth factor receptor-mutant non-small cell lung cancer receiving almonertinib who developed a broad-based posterior wall left ventricular mass while cancer imaging remained stable. At detection, the reported left ventricular ejection fraction estimate was 55%, and no regional wall motion abnormality was documented. Cardiac CT showed no calcification or appreciable arterial- or delayed-phase enhancement, and Doppler echocardiography showed no internal flow. Low-mechanical-index contrast-enhanced echocardiography showed no appreciable internal perfusion in the contemporaneous examination report; later archived images also showed persistent absence of perfusion, although early-phase cine loops were not retained for retrospective reassessment. These concordant avascular features supported the presence of a thrombus but were not diagnostic. Cardiac magnetic resonance was recommended but declined because of financial concerns, and histopathology was unavailable. After approximately 9 months of prescribed edoxaban 60 mg once daily with reported adherence, the maximum linear dimension increased from 39.7 to 51.0 mm. A posterior wall regional wall motion abnormality was first documented 5 months after mass detection and therefore could not explain the lesion already present at detection. Edoxaban levels and edoxaban-calibrated anti-factor Xa activity were not measured, and human interaction data for almonertinib and edoxaban were unavailable. This case highlights the need to keep the diagnosis qualified and to reassess alternative pathology and anticoagulant exposure when an imaging-supported left ventricular thrombus follows an unexpected course.
Related
- Evaluation of Individualized Sequential Therapy Centered on Surgical Excision and Superficial Radiotherapy in Treating Keloids in the Anterior Chest Wall
- Warfarin for Left Ventricular Thrombus in Nonischemic Cardiomyopathy With Acute Kidney Injury: A Case Report and Literature Review of Anticoagulation Strategies in Renal Impairment.
- Estimating Individualized Survival Benefit of Consolidative Metastasis-Directed Radiotherapy Following Chemoimmunotherapy in Nasopharyngeal Carcinoma With Exclusive Distant Metastasis.
- Cardiac Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia — Target Definition, Dose Distribution, and Clinical Trajectory —
- Cellular consequences of non-ablative radiotherapy: A novel approach to ventricular tachycardias
BibTeX
@article{he2026case,
title = {{Case Report: An enlarging left ventricular mass during anticoagulation in a patient receiving almonertinib after thoracic radiotherapy: diagnostic uncertainty and individualized management}},
author = {Bin He and Yu Tan and Fangyuan Kong and Hua Li and Ling Zhang},
journal = {Frontiers in cardiovascular medicine},
year = {2026},
month = sep,
doi = {10.3389/fcvm.2026.1953416},
url = {https://europepmc.org/article/PMC/PMC13661977},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case Report: An enlarging left ventricular mass during anticoagulation in a patient receiving almonertinib after thoracic radiotherapy: diagnostic uncertainty and individualized management
AU - Bin He
AU - Yu Tan
AU - Fangyuan Kong
AU - Hua Li
AU - Ling Zhang
PY - 2026
DA - 2026/09/30
JO - Frontiers in cardiovascular medicine
DO - 10.3389/fcvm.2026.1953416
UR - https://europepmc.org/article/PMC/PMC13661977
AB - Distinguishing a left ventricular thrombus from a cardiac tumor is challenging when a large mass arises at an atypical non-apical site, particularly in a patient with cancer. We describe a 37-year-old man with epidermal growth factor receptor-mutant non-small cell lung cancer receiving almonertinib who developed a broad-based posterior wall left ventricular mass while cancer imaging remained stable. At detection, the reported left ventricular ejection fraction estimate was 55%, and no regional wall motion abnormality was documented. Cardiac CT showed no calcification or appreciable arterial- or delayed-phase enhancement, and Doppler echocardiography showed no internal flow. Low-mechanical-index contrast-enhanced echocardiography showed no appreciable internal perfusion in the contemporaneous examination report; later archived images also showed persistent absence of perfusion, although early-phase cine loops were not retained for retrospective reassessment. These concordant avascular features supported the presence of a thrombus but were not diagnostic. Cardiac magnetic resonance was recommended but declined because of financial concerns, and histopathology was unavailable. After approximately 9 months of prescribed edoxaban 60 mg once daily with reported adherence, the maximum linear dimension increased from 39.7 to 51.0 mm. A posterior wall regional wall motion abnormality was first documented 5 months after mass detection and therefore could not explain the lesion already present at detection. Edoxaban levels and edoxaban-calibrated anti-factor Xa activity were not measured, and human interaction data for almonertinib and edoxaban were unavailable. This case highlights the need to keep the diagnosis qualified and to reassess alternative pathology and anticoagulant exposure when an imaging-supported left ventricular thrombus follows an unexpected course.
SN - 2297-055X
ER -